BioRegenx, Inc. (BRGX)
OTC Markets OTCPK
Price as at 30 Sept 2026, 16:40 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
BioRegenx, Inc. trades at $0.01. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About BioRegenx, Inc.
BioRegenx, Inc. engages in the research, development, and commercialization of dietary supplements, medical devices, software, and contactless diagnostic technologies in the United States and internationally. The company offers DocSun AI engine, which integrates with a ballistocardiograph that detects an individual's heartbeat; TruScan.AI mobile app for additional health indications; VitalWellness app for DNA and epigenetics platform; and Endocalyx Pro, a dietary supplement targeting microvascular capillary health. It also provides MyBodyRx, a supplement; GlycoCheck software and medical devices; hydrogen water products and health and wellness devices, such as pulsed electro-magnetic field devices; StimaWELL and ReLounge electronic muscle stimulation therapy devices; and Findit.com, a social media content management platform. The company sells its products through a direct selling channel to health professionals and research organizations. BioRegenx, Inc. is headquartered in Chattanooga, Tennessee.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Common questions
Where does SteadyShares get its BRGX data?
Fundamentals for BRGX come from company filings and exchange data, as listed on OTC Markets OTCPK; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 30 Sept 2026, 16:40 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for BRGX, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.